March 26 (Reuters) - Vascular Biogenics Ltd:
* VBL THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS IN OVAL PHASE 3 OVARIAN CANCER PIVOTAL STUDY
* VASCULAR BIOGENICS LTD - OVERALL CA-125 RESPONSE RATE IN FIRST 60 RANDOMIZED EVALUABLE PATIENTS IS 53%
* VASCULAR BIOGENICS LTD - OVAL DSMC REVIEWED UN-BLINDED DATA AND DETERMINED THAT STUDY HAS MET INTERIM PRE-SPECIFIED CRITERION
* VASCULAR BIOGENICS LTD - DSMC RECOMMENDS THAT STUDY PROCEED WITHOUT MODIFICATION.
* VASCULAR BIOGENICS- CA-125 RESPONSE RATE OBSERVED IN PHASE 3 INTERIM ANALYSIS IS AT LEAST AS GOOD AS RESPONSE RATE SEEN IN PHASE 2 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.